These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24356621)

  • 1. Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer.
    Sota Y; Naoi Y; Tsunashima R; Kagara N; Shimazu K; Maruyama N; Shimomura A; Shimoda M; Kishi K; Baba Y; Kim SJ; Noguchi S
    Ann Oncol; 2014 Jan; 25(1):100-6. PubMed ID: 24356621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
    Kim SJ; Nakayama S; Shimazu K; Tamaki Y; Akazawa K; Tsukamoto F; Torikoshi Y; Matsushima T; Shibayama M; Ishihara H; Noguchi S
    Ann Oncol; 2012 Apr; 23(4):891-7. PubMed ID: 21821547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
    BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
    O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
    Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
    Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients.
    Oda N; Shimazu K; Naoi Y; Morimoto K; Shimomura A; Shimoda M; Kagara N; Maruyama N; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2012 Nov; 136(1):107-16. PubMed ID: 22986814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m
    Kojima Y; Kawamoto H; Nishikawa T; Hayami R; Shimo A; Haku E; Akiyama K; Tsugawa K
    Clin Breast Cancer; 2018 Oct; 18(5):374-379. PubMed ID: 29452759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
    Ayers M; Symmans WF; Stec J; Damokosh AI; Clark E; Hess K; Lecocke M; Metivier J; Booser D; Ibrahim N; Valero V; Royce M; Arun B; Whitman G; Ross J; Sneige N; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2004 Jun; 22(12):2284-93. PubMed ID: 15136595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
    Stickeler E; Pils D; Klar M; Orlowsk-Volk M; Zur Hausen A; Jäger M; Watermann D; Gitsch G; Zeillinger R; Tempfer CB
    Oncol Rep; 2011 Oct; 26(4):1037-45. PubMed ID: 21769435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of multi-gene classifier for prediction of response to and prognosis after neoadjuvant chemotherapy for estrogen receptor positive breast cancers.
    Tsunashima R; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Cancer Lett; 2015 Sep; 365(2):166-73. PubMed ID: 26052094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
    Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
    BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
    Ando M; Yamauchi H; Aogi K; Shimizu S; Iwata H; Masuda N; Yamamoto N; Inoue K; Ohono S; Kuroi K; Hamano T; Sukigara T; Fujiwara Y
    Breast Cancer Res Treat; 2014 Jun; 145(2):401-9. PubMed ID: 24728578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
    Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Wang Q; Li C; Tang P; Ji R; Chen S; Wen J
    Cell Physiol Biochem; 2018; 48(6):2539-2548. PubMed ID: 30121642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.